platoseedplatoseed
Creating new protein-based drugs at scale
Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.
Invitris is a biotechnology company focusing on cell-free protein synthesis to enable rapid design, expression, and scalable production of complex proteins. It positions itself as a manufacturing engine for AI-enabled medicine and rapid biotech workflows. The company emphasizes speed, flexibility, and scalable production across prokaryotic and mammalian cell-free systems.
Invitris offers cell-free protein synthesis platforms, including Prokaryotic and Mammalian Cell-Free Expression Systems. The Prokaryotic system provides high-yield expression with streamlined purification using Phactory reagents and supports E. coli codon-optimized DNA with T7 promoters. The Mammalian system enables complex proteins with post-translational modifications (glycosylation, disulfide bonds) without transfection, delivering scalable, high-yield expression of difficult proteins. The platform enables rapid design, expression, and scalable production, supports ultra high-throughput screening (up to 1,000 proteins per second) via microfluidics, and integrates rapid protein engineering from sequence to structure. The company offers scalable production from picoliter to liter-scale and facilitaes co-development and licensing for market-ready solutions, including translational production up to GMP manufacturing.
Who it’s for: Life sciences and biopharma researchers, biotech startups, pharmaceutical developers, and organizations needing rapid, scalable production of complex proteins or AI-driven drug development workflows.
news mentions, grants, and spin-off milestones referenced (funding and awards cited on site)
My hearts are entrepreneurship & science, originally trained as bioinformatician at the Harvard Medical School and ETH Zurich amongst other schools. I earned a PhD and MBA, and highly enjoy opportunities to improve the world with science-based products. I co-founded Invitris to radically simplify drug development to stop antibiotic-resistance, which has the potential to become the dominating health-economic challenge in this century.
Kilian, the CTO and co-founder of Invitris, is responsible for driving innovation and development within the company. With a PhD in synthetic biology from TUM and a track record of 5 patents, his expertise has been instrumental in creating Invitris' groundbreaking technology.
Our biotech platform creates the newest drugs in shortest time
Invitris presents Phactory, a platform that turns DNA into synthetic proteins to produce protein-based drugs, starting with bacteriophages, aiming to make development more scalable and reduce material costs. The company targets biopharmaceutical partners and collaborators in antibacterial and related protein-synthesis applications.
From the original launch (Mar 2023) — may be outdated.
Generative AI for protein design
Data analytics software for biomanufacturing.
